Scc-Ag、CA19-9、CEA联合测定对肺癌临床诊断的价值  

Value of Combined Determination of SCC-Ag,CA19-9 and CEA for the Diagnosis of Lung Cancer

作　　者：罗耀凌[1] 欧国萍[1] 邱瑞芬 李小东[1] 吴兴平[1] 雷穗妮[1] 

机构地区：[1]中山医科大学肿瘤防治中心,510060

出　　处：《实用癌症杂志》2001年第2期168-170,共3页The Practical Journal of Cancer

摘　　要：目的　评价血清鳞癌抗原 (Scc Ag)、癌糖类抗原 (CA19 9)和癌胚抗原 (CEA )水平的测定对肺癌临床诊断的价值。方法　采用微粒子酶免疫法测定 78例肺癌、45例良性肺病患者的血清Scc Ag、CA 19 9和CEA水平 ,评价 3项指标联合应用的诊断价值。结果　肺癌组患者血清Scc Ag、CA 19 9和CEA水平明显高于健康对照组和良性肺病组 (P <0 .0 1) ,联合应用敏感性达70 .5 %。临床分期越晚 ,Scc Ag、CA 19 9和CEA水平和阳性率越高。Scc Ag检测的阳性率以鳞癌最高 (6 4.3 % ) ;CA 19 9+CEA检测的阳性率以腺癌最高 (71.1% )。结论　该 3项肿瘤标志物联合检测可提高肺癌的诊断率 ,并对判断病情及病理类型有较大帮助 。Objective To evaluate the value of serum squamous cell antigen(Scc Ag),cancer antigen 19 9(CA19 9) and carcinoembryanic antigen(CEA) determination for diagnosis of lung cancer.Methods The serum levels of Scc Ag,CA19 9 and CEA were determined by Microparticle Enzyme Immunoassay(MEIA) in 78 cases of lung cancer and 45 cases of benign lung diseases.To evaluate diagnostic value of combination.Results The serum levels of Scc Ag,CA19 9 and CEA in the patients with lung cancer were significantly higher than in those patients with benign lung disease( P <0.01).Combined determination of these tumor markers increased the diagnostic sensitivity to 70.5%.The serum levels of these markers in patients with advanced disease(stage Ⅲ and Ⅳ) were significantly higher than in those with stage Ⅰ and Ⅱ.There was higher Scc Ag positive rate in squamous cell carcinoma (64.3%) and higher CA19 9 and CEA positive rate in adenocarcinomas(71.1%).Conclusion The Combination determination of three tumor markers can increase diagnosis rate of lung cancer,also can be used for judging development of the disease and pathological type,but they are not sensitive to early diagnosis.

关 键 词：肺癌 鳞癌抗原 癌糖类抗原19-9 癌胚抗原 诊断 

分 类 号：R734.2[医药卫生—肿瘤] R730.43[医药卫生—临床医学]